Nasdaq · Biotech stocks database
CYRX — CryoPort Inc. ☆
CYRX (CryoPort Inc.) stock: $19.10, $967.4M market cap, $393.1M cash, $574.3M EV, $1.27B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
What they do
We are a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with a strong focus on supporting the rapidly growing cell and gene therapy (“CGT”) market. Our solutions are purpose-built to support a broad range of global life sciences markets, including biopharmaceutical and pharmaceutical companies, the animal health markets, reproductive medicine, academic institutions, research, and government agencies.
Source: 10-K FY2025 via SEC EDGAR
Balance sheet
Cash $393.1M Debt $0.0M Net cash $393.1M Enterprise value $574.3M Basic shares 50.7M shares Fully diluted shares 66.7M shares Fully diluted market cap $1,273.2M Cash per share $7.75 Quarterly burn +$1.1M generated
Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.
Share structure
Cap table as of 2026-07-31.
Price history Loading CYRX daily closes…
Loading price history…
Asset data not yet available for this company.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.